newsfilter
← Latest News
Business Wire·

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

  • Turn Therapeutics Inc. (NASDAQ: TTRX) announced that CEO Bradley Burnam & Executive Clinical & Regulatory Lead Stephen M. Hahn will present at the Stifel 2026 Virtual Immunology & Inflammation Forum.
  • The presentation is scheduled for September 23, 2026, at 1:30 PM ET.
  • The session will detail the company's atopic dermatitis clinical program, including a pruritus-focused stage 2 enrichment strategy & emerging findings across specific patient populations.
  • Key patient cohorts discussed include those with moderate-severe baseline pruritus & a group characterized by lower EASI scores despite high investigator-assessed disease severity.
  • A live webcast will be available on the company's Investor Relations website, with a replay accessible for approximately six months post-presentation.
  • Turn Therapeutics develops targeted, non-systemic therapies acting directly at the disease site, with its lead candidate GX-03 currently evaluated for atopic dermatitis & onychomycosis.
  • The company's research focuses on the intersection of microbial activity, local immune signaling, & chronic inflammation.